Palevsky named president of NKF board of directors
Click Here to Manage Email Alerts
The National Kidney Foundation has announced in a press release that it has named Paul M. Palevsky, MD, president of the organization’s board of directors.
Palevsky, a nephrologist, professor of medicine at the University of Pittsburgh School of Medicine and the chief of kidney medicine at the VA Pittsburgh Healthcare System, will serve a 2-year term replacing outgoing president Holly Kramer, MD, MPH.
Palevsky, a past recipient of the NKF’s J. Michael Lazarus Distinguished Award for novel insights related to renal replacement therapy, is internationally recognized as an expert in AKI and critical care nephrology. He also leads multiple clinical trials focused on management of acute dialysis, acute kidney injury prevention and slowing the progression of diabetic kidney disease, the release noted.
“I am honored and humbled by the opportunity to help lead the National Kidney Foundation and to advocate for the estimated 37 million adults in the U.S. with kidney disease and the millions more at risk,” Palevsky said in the release. “The COVID-19 pandemic has made apparent the vulnerabilities of patients with kidney disease and has highlighted disparities in medical care, particularly among minority communities, that we must address.”
The NKF board of directors is comprised of community leaders who have been affected by kidney disease, including nephrologists, kidney health care professionals, living donors, transplant recipients, care partners, top executives with diverse business experience and civic leaders. Board members serve a term of 3 years and may be elected for a second term.
Read more about
Click Here to Manage Email Alerts